Related Experiment Video

Updated: May 23, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis

Naoko Okumura1, Hitomi Yoshida, Yasuko Kitagishi

  • 1Department of Environmental Health Science, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan.

Advances in Hematology
|April 17, 2012
PubMed

Insights

The PI3K/AKT/PTEN pathway regulates angiogenesis in leukemia. Understanding this pathway

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Research
  • Leukemia Pathogenesis

Background:

  • The Phosphatidylinositol 3-kinase/Protein kinase B/Phosphatase and tensin homolog (PI3K/AKT/PTEN) pathway is crucial for regulating vascular endothelial growth factor (VEGF)-mediated angiogenesis.
  • This pathway is frequently dysregulated in various cancers, including leukemia.
  • Aberrant activation of this pathway, often associated with decreased PTEN expression, contributes to tumor growth and progression.

Purpose of the Study:

  • To elucidate the roles and mechanisms of the PI3K/AKT/PTEN pathway in regulating angiogenesis within the context of leukemia.
  • To highlight the therapeutic potential of targeting this pathway for leukemia treatment.

Main Methods:

  • Review of existing literature on the PI3K/AKT/PTEN pathway and its role in angiogenesis.
  • Analysis of studies investigating pathway activation and PTEN expression in leukemia patients and cell lines.
  • Examination of the molecular mechanisms linking PI3K/AKT/PTEN signaling to VEGF-mediated angiogenesis.

Main Results:

  • The PI3K/AKT/PTEN pathway is activated in leukemia, correlating with reduced PTEN gene expression.
  • This pathway plays a significant role in mediating VEGF-induced angiogenesis, a critical process for leukemia cell proliferation and survival.
  • The precise mechanisms by which this pathway regulates angiogenesis require further investigation.

Conclusions:

  • The PI3K/AKT/PTEN pathway is a key regulator of angiogenesis in leukemia.
  • Targeting this pathway presents a promising therapeutic strategy for leukemia drug development due to its role in malignant cell growth.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...